Novartis Sees Sales Growth Through Next Round of Patent Expirations

Novartis projected annual sales growth of 5% from 2026 to 2031, excluding currency effects, to address investor concerns regarding upcoming patent expirations.
Novartis Sees Sales Growth Through Next Round of Patent Expirations

A facts-only brief, written by a local AI model from this article in The Wall Street Journal, November 19, 2026. It may contain mistakes, and it is not the article: the full story is at wsj.com.

Novartis projected annual sales growth of 5% from 2026 to 2031, excluding currency effects, to address investor concerns regarding upcoming patent expirations. CEO Vas Narasimhan stated at a London event on Thursday that the company is integrating artificial intelligence into its operations to accelerate clinical trials and improve success rates. The executive noted that AI aims to raise the probability of trial success to 12% and reduce drug development cycles to eight years, compared to current industry averages of 8% and 12 years, respectively. Novartis also raised peak sales estimates for Kesimpta, Scemblix, and Leqvio, reinforcing its confidence in the mid-term outlook.

Background

  • The Swiss drugmaker faces the loss of U.S. patent protection for key drugs, including Cosentyx, Kisqali, and Kesimpta, between 2029 and 2031.
  • Novartis reported that it currently has nine in-market products with potential peak annual sales between $3 billion and $10 billion, alongside ten late-stage pipeline candidates.
  • The company expects to return to a core operating profit margin above 40% by 2029 and plans to continue targeting acquisitions predominantly valued below $2 billion.
  • Shares in Novartis declined 3.2% in European midday trading following the announcement.

Read the full article at wsj.com

More from Thursday, November 19:

Referenced article not yet available naddr1qqt8wu…rse2skz7


Write a comment